Lindsey Roeker, MD, practices as a hematologic oncologist as the Memorial Sloan Kettering Cancer Center, Commack, NY, where she specializes in chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other lymphoproliferative disorders.
Dr Roeker earned her medical degree from the Mayo Clinic School of Medicine, Rochester, MN, before taking on a residency in internal medicine at Brigham and Women’s Hospital, Boston, MA. She recently completed a hematology and medical oncology fellowship at the Memorial Sloan Kettering Cancer Center, during which she earned MSKCC Chief Fellow in 2018 and the 2019 ASH Research Training Award for Fellows. Dr Roeker is a committed physician and researcher, and in her role as a member of the MSK CLL program, she develops and leads clinical trials of novel agents in CLL.
Speaking on early phase clinical trials of novel agents in CLL
Dr Roeker’s research is motivated by a goal of innovatively moving the CLL field forward with novel agents and immunotherapies. She has led and been involved in a number of early phase clinical trials, including the recent investigations into LOXO-305, APR-246 and CG-806.